Regeneron antibody restores muscle loss in patients after stopping Wegovy, mid-stage data show

Regeneron presented new mid-stage data at the European Association for the Study of Diabetes (EASD) meeting in Milan showing its investigational antibody can help patients with obesity recover muscle mass after they discontinue Novo Nordisk’s GLP-1 agonist Wegovy.

The analysis compared muscle loss experienced while on Wegovy with muscle gain after stopping the drug, finding that participants regained a comparable amount of lean tissue when treated with Regeneron’s antibody.

The findings suggest the antibody could address a known concern of muscle loss associated with GLP-1 therapies, potentially improving long-term outcomes for patients who need to discontinue treatment.